Comparative Pharmacology
Head-to-head clinical analysis: SPS versus VELTASSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPS versus VELTASSA.
SPS vs VELTASSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
VELTASSA (patiromer) is a non-absorbed polymer that binds potassium ions in the gastrointestinal tract, reducing serum potassium levels by increasing fecal potassium excretion.
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
8.4 g (1 packet) orally once daily; titrate to a maximum of 25.2 g (3 packets) once daily as needed to achieve normokalemia.
None Documented
None Documented
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
Not applicable due to non-systemic action; patiromer acts locally in the gastrointestinal tract and is not absorbed. Elimination half-life of the polymer is not measurable clinically.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Primarily eliminated via feces as insoluble, non-absorbed polymer (80-90%); minimal renal excretion (<0.01% of administered dose as intact drug in urine), biliary excretion negligible.
Category C
Category C
Potassium Binder
Potassium Binder